TrialJournal of gynecologic oncology2026

Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Jung-Yun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.